Skip to content

Study · Randomized controlled trial · n = 267 · 2026

8 results

Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.

Ambika Gopalakrishnan U, Joshi A, Kumar H, Giri R, Maheshwari S, Prasad VS, Shukla J, M Chowdaiah R, Agrawal NK, Rasal Y, Sahoo B, Bhandari S and 15 more

Show all authors

Gowda A, Phadke U, Supe P, Pathak N, Chandrappa A, Sonawane A, Bahulikar Y, Bhaskar A, Radhakrishnan A, Yadav P, Pandit S, Sonowal S, Patil D, Ghadge P, Mehta S

Diabetes, obesity & metabolism6 Jul 2026Cited by 2 (Europe PMC)

PMID42403263 (opens in a new tab)PMCIDPMC13449013 (opens in a new tab)DOI10.1111/dom.71069 (opens in a new tab)PepBankPUB-42403263
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, test semaglutide was non-inferior to reference semaglutide for percent weight change at week 24.

    In plain wordsIn adults with obesity or overweight, a synthetic semaglutide led to about the same weight loss at 24 weeks as Wegovy.

    Peptide
    Semaglutide
    Outcome
    No significant changePercent weight change from baseline at week 24
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Measurements

    Mean percent weight change
    −13.8%
    Test
    Mean percent weight change
    −14.1%
    Reference
    LS mean difference
    0.26%
    Test vs Reference

    Source sentences

    Summary
    At Week 24, mean percent weight change from baseline was -13.8% ± 4.28% in Test and -14.1% ± 4.11% in Reference groups with least-squares mean difference of 0.26% (95% CI: -0.86% to 1.39%), meeting the criterion for non-inferiority.
    2 context sentences
    Summary · context
    The primary endpoint was percentage change in bodyweight from baseline to Week 24.
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, the proportion with weight loss of 5% or more at week 24 was 96.40% with test and 98.80% with reference semaglutide.

    In plain wordsIn adults with obesity or overweight, nearly everyone lost at least 5% of weight at 24 weeks with both semaglutide products.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedWeight loss of 5% or more
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Measurements

    Proportion with 5% or more weight loss
    96.4%
    Test
    Proportion with 5% or more weight loss
    98.8%
    Reference

    Source sentences

    Summary
    The proportion of patients with ≥ 5% and ≥ 10% weight loss were 96.40% and 80.60% in Test, and 98.80% and 80.00% in Reference groups, respectively at Week 24.
    1 context sentence
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, the proportion with weight loss of 10% or more at week 24 was 80.60% with test and 80.00% with reference semaglutide.

    In plain wordsIn adults with obesity or overweight, about 80% lost at least 10% of weight at 24 weeks with both semaglutide products.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedWeight loss of 10% or more
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Measurements

    Proportion with 10% or more weight loss
    80.6%
    Test
    Proportion with 10% or more weight loss
    80%
    Reference

    Source sentences

    Summary
    The proportion of patients with ≥ 5% and ≥ 10% weight loss were 96.40% and 80.60% in Test, and 98.80% and 80.00% in Reference groups, respectively at Week 24.
    1 context sentence
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, improvements in body mass index were comparable between test and reference semaglutide.

    In plain wordsIn adults with obesity or overweight, BMI improved by a similar amount with both semaglutide products.

    Peptide
    Semaglutide
    Outcome
    No significant changeBody mass index improvement
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in body mass index, waist circumference, SF-36 total score, and glycemic parameters were comparable between groups.
    1 context sentence
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, improvements in waist circumference were comparable between test and reference semaglutide.

    In plain wordsIn adults with obesity or overweight, waist size improved by a similar amount with both semaglutide products.

    Peptide
    Semaglutide
    Outcome
    No significant changeWaist circumference improvement
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in body mass index, waist circumference, SF-36 total score, and glycemic parameters were comparable between groups.
    1 context sentence
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, improvements in SF-36 total score were comparable between test and reference semaglutide.

    In plain wordsIn adults with obesity or overweight, quality-of-life scores improved by a similar amount with both semaglutide products.

    Peptide
    Semaglutide
    Outcome
    No significant changeSF-36 total score improvement
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in body mass index, waist circumference, SF-36 total score, and glycemic parameters were comparable between groups.
    1 context sentence
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, improvements in glycemic parameters were comparable between test and reference semaglutide.

    In plain wordsIn adults with obesity or overweight, blood sugar measures improved by a similar amount with both semaglutide products.

    Peptide
    Semaglutide
    Outcome
    No significant changeGlycemic parameters improvement
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in body mass index, waist circumference, SF-36 total score, and glycemic parameters were comparable between groups.
    1 context sentence
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.
  8. 08HumanRandomized controlled trialSafety outcome

    In adults with obesity or overweight, treatment-emergent adverse events occurred in 72.30% with test and 76.70% with reference semaglutide, mostly gastrointestinal.

    In plain wordsIn adults with obesity or overweight, side effects were reported by about three in four people on either semaglutide product, mostly stomach and gut ones.

    Peptide
    Semaglutide
    Outcome
    Not applicableTreatment-emergent adverse events
    Study

    n = 267

    Comparator
    Wegovy (Reference semaglutide)
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.25 to 2.4 mg · 24 weeksAs given in this study (human).

    Measurements

    TEAE incidence
    72.3%
    Test
    TEAE incidence
    76.7%
    Reference

    Source sentences

    Summary
    Treatment-emergent adverse events were reported in 72.30% and 76.70% in the Test and Reference groups, respectively, with gastrointestinal events being the most common.
    1 context sentence
    Summary · context
    This randomized, Phase III, non-inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.